As a leader in plasma collection, CSL Plasma is committed to excellence and innovation in everything we do. Our work helps to ensure that tens of thousands of people are able to live normal, healthy lives. We are committed to our work because lives depend on us.
CSL Plasma operates one of the world’s largest and most sophisticated plasma collection networks, with more than 270 plasma collection centers in U.S., Europe and China and employs over 12,000 employees.
CSL Plasma is vertically integrated, meaning plasma collected at CSL Plasma facilities is used by CSL Behring for the sole purpose of manufacturing and delivering its life-saving therapies to people in more than 70 countries.
CSL Plasma is a subsidiary of CSL Behring, a global biotech leader and a member of the CSL Group of companies. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia.
The Commonwealth Serum Laboratories was established in Australia in 1916 to service the health needs of a nation isolated by war. Over the ensuing years CSL provided Australians with rapid access to 20th century medical advances including insulin and penicillin, and vaccines against influenza, polio and other infectious diseases. CSL Limited was incorporated in 1991 and listed on the Australian Securities Exchange (ASX) in 1994.
Since then, CSL has acquired a number of companies. They include: Aventis Behring, which is now known as global biotech leader CSL Behring, U.S. plasma collector Nabi, which helped to form the world's premier plasma collection company in CSL Plasma, the Novartis influenza vaccine business, now integrated and known as Seqirus, the world's second largest influenza vaccines company and Calimmune, a leader in gene-modification and cell delivery technology. Their combined and rich histories make CSL the innovative global leader it is today.